ArticleBMC nephrology2025
Therapeutic effects of Gancao Xiexin Decoction on renal ischemia-reperfusion injury based on network pharmacology and experimental validation.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRenal ischemia-reperfusion injury (IRI) is a common clinical condition that triggers a complex cascade of biological responses, including inflammation, oxidative stress, and apoptosis. These responses can lead to impaired renal function and acute kidney injury (AKI). Despite advancements in therapeutic agents, there is still a need for safe and effective drugs. In this study, we investigated the therapeutic effects and mechanisms of Gancao Xiexin Decoction (GCXXD), an herbal compound known for its anti-inflammatory, antioxidant, and immunomodulatory properties, in treating renal IRI.
methodsWe utilized network pharmacology to identify the intersection targets of the active ingredients in GCXXD and AKI. Cytoscape software was used to obtain core targets, and the String database was used to map the interaction network of these targets. GO and KEGG enrichment analyses were conducted to assess the biological functions and potential pathways involved. Molecular docking simulations were performed to examine the binding of the main active components of GCXXD to the key pathways. Validation experiments were conducted using an IRI mouse model and a hypoxia-reoxygenation-mediated HK2 injury model.
resultsA total of 11 core targets of GCXXD for the treatment of AKI were identified. GO and KEGG analyses revealed enrichment in biological functions related to oxidative stress, apoptosis, and the PI3K/AKT signaling pathway. Molecular docking results indicated strong binding affinity between the key active components (baicalein, ginsenoside Rh2, quercetin, and wogonin) of GCXXD and the PI3K/AKT pathway. In both in vivo and ex vivo experiments, GCXXD activated the PI3K/AKT pathway and ameliorated renal IRI.
conclusionThis study demonstrated that GCXXD effectively improved ischemia-reperfusion-induced renal injury primarily via activating the PI3K/AKT pathway. These findings provided a scientific basis for the clinical application of GCXXD and paved the way for the development of new drugs and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.